Given the known occurrence of treatment resistance to tamoxifen in HR-positive, HER2-positive breast cancers, we conducted a comparison of outcomes to determine whether this phenomenon persisted in HER2-low breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.